|By Marketwired .||
|July 25, 2014 04:30 PM EDT||
MINNEAPOLIS, MINNESOTA -- (Marketwired) -- 07/25/14 -- DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, today announced that at its Annual General and Special Meeting (the "Meeting") of shareholders held on July 24, 2014, Michael Giuffre, Rick Pauls, Richard Pilnik, Dawson Reimer and Thomas Wellner were re-elected as the Company's board of directors.
In addition to the election of directors, the shareholders passed all resolutions placed before the Meeting as outlined in the management information circular (the "Circular") dated June 26, 2014. As more particularly described in the Circular, the additional resolutions included re-appointing KPMG LLP as auditors for the upcoming year; approving the continuance of the Company under the Canada Business Corporations Act; authorizing the Company's board of directors to amend the Articles of Incorporation to consolidate the outstanding common shares on the basis of one post-consolidation common share for each two to ten pre-consolidation common shares; approving certain amendments to the Company's by-laws; and renewing the shareholder rights plan of the Company.
DiaMedica Inc. is a publicly traded (TSX VENTURE: DMA) clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases. DiaMedica's lead clinical stage product, DM199, recombinant human tissue kallikrein-1 protein ("rhKLK-1"), is a novel, first-in-class, therapeutic for the treatment of diabetes mellitus and associated complications. DiaMedica also is developing DM204, a monoclonal antibody program, for glucose control and cardiovascular complications in type 2 diabetes and a companion diagnostic in vitro assay, DMDx, utilizing the detection of tissue kallikrein-1 protein ("KLK-1") as a potential biomarker in human urine to identify diabetic kidney disease patients who are most likely to respond to a therapeutic regimen that includes DM199.
The Company is listed on the TSX Venture Exchange in Canada under the trading symbol 'DMA'.
The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, including the intended use of the net proceeds of the Offering, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in DiaMedica's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.
Chief Financial Officer
One Carlson Parkway, Suite 124
Mar. 29, 2017 09:15 AM EDT Reads: 511
Mar. 29, 2017 09:00 AM EDT Reads: 529
Mar. 29, 2017 08:45 AM EDT Reads: 882
Mar. 29, 2017 08:00 AM EDT Reads: 7,428
Mar. 29, 2017 06:30 AM EDT Reads: 6,254
Mar. 29, 2017 06:00 AM EDT Reads: 9,044
Mar. 29, 2017 06:00 AM EDT Reads: 2,829
Mar. 29, 2017 05:00 AM EDT Reads: 6,417
Mar. 29, 2017 04:00 AM EDT Reads: 3,192
Mar. 29, 2017 04:00 AM EDT Reads: 15,087
Mar. 29, 2017 03:45 AM EDT Reads: 2,144
Mar. 29, 2017 03:30 AM EDT Reads: 3,363
Virtualization over the past years has become a key strategy for IT to acquire multi-tenancy, increase utilization, develop elasticity and improve security. And virtual machines (VMs) are quickly becoming a main vehicle for developing and deploying applications. The introduction of containers seems to be bringing another and perhaps overlapped solution for achieving the same above-mentioned benefits. Are a container and a virtual machine fundamentally the same or different? And how? Is one techn...
Mar. 29, 2017 03:30 AM EDT Reads: 3,219
Mar. 29, 2017 03:30 AM EDT Reads: 11,766
My team embarked on building a data lake for our sales and marketing data to better understand customer journeys. This required building a hybrid data pipeline to connect our cloud CRM with the new Hadoop Data Lake. One challenge is that IT was not in a position to provide support until we proved value and marketing did not have the experience, so we embarked on the journey ourselves within the product marketing team for our line of business within Progress. In his session at @BigDataExpo, Sum...
Mar. 29, 2017 03:30 AM EDT Reads: 3,227